FACS-Based Screening for Stable High-Producing Therapeutic Protein Clones

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current methods for identifying high-producing clones for therapeutic protein production are time-consuming and labor-intensive, and existing screening methods do not accurately predict clones with high specific productivity and titer, especially at the 96-well plate stage of cell line development.

Innovation Solution

The use of recombinant eukaryotic host cells containing a polynucleotide with a promoter element, a cell surface marker polypeptide, and a target polypeptide, along with an internal ribosome entry site (IRES) or alternate start codon, allows for the selection and isolation of cells with high expression levels of the cell surface marker, indicating stable and high expression of the target polypeptide, using fluorescence-activated cell sorting (FACS) for accurate screening.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If repeated selection based amplification using methotrexate is used to obtain high producing clones, then stable high expressing recombinant cell lines can be obtained, but the process becomes time-consuming and labor intensive

Engineering Contradiction:

Improvestable high expressing recombinant cell lineVSAvoidtime-consuming process

Core Design Contradiction:

ReliabilityVSLoss of time

Solution Approach 1:

The patent applies preliminary action by using FACS to screen and identify high-producing clones early in the cloning process, before the time-consuming MTX amplification steps. This allows the selection of promising clones at the 96-well plate stage, enabling parallel processing and reducing the overall time required to obtain stable high-expressing cell lines.

Inventive Principle:

Principle #10Preliminary action

Solution Approach 2:

The patent replaces the mechanical/manual screening process with automated FACS technology. Instead of manually assessing clone production through media harvesting and analysis, the system uses fluorescence-activated cell sorting to automatically identify and isolate high-producing clones based on fluorescent marker expression, significantly reducing labor and time requirements.

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

2Measurement precision

If analysis of cell culture media harvests is used to identify clones secreting high levels of therapeutic protein, then protein production can be assessed, but the method does not account for differences in cell density or media volume between wells

Engineering Contradiction:

Improveprotein production assessmentVSAvoidspecific productivity and titer prediction

Core Design Contradiction:

Measurement precisionVSManufacturing precision

Solution Approach 1:

The patent introduces a fluorescent marker protein as an intermediary that is co-expressed with the therapeutic protein. This marker serves as a proxy that can be directly measured on cell surfaces via FACS, providing a normalized measure of protein production that accounts for differences in cell density and media volume between wells, thereby improving measurement precision and predictive accuracy.

Inventive Principle:

Principle #24Intermediary (Mediator)

3Measurement precision

If a new assay is developed for each new therapeutic protein of interest, then specific protein production can be measured, but effort and time must be spent on assay development and optimization

Engineering Contradiction:

Improveprotein-specific measurementVSAvoidassay development and optimization time

Core Design Contradiction:

Measurement precisionVSLoss of time

Solution Approach 1:

The patent employs a universal fluorescent marker protein system that can be applied across different therapeutic proteins. The same FACS-based screening methodology and marker protein framework can be used for multiple different therapeutic proteins, eliminating the need to develop new assays from scratch for each protein and significantly reducing time and effort requirements.

Inventive Principle:

Principle #6Universality (Multi-functionality)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

This method enables efficient and accurate identification of stable, high-producing clones at the 96-well plate stage, reducing the time and effort required for clone screening and ensuring high protein titers upon scale-up, while also allowing for the early elimination of unstable clones.

Implementation Method 1

a polynucleotide having the biological activity of an internal ribosome entry site (IRES) polynucleotide, and wherein the IRES polynucleotide is located within the recombinant polynucleotide such that the cell surface marker polynucleotide and the target polynucleotide are transcribed on the same mRNA

Methodology Applied

Scientific EffectInternal ribosome entry site (IRES):

Implementation Method 2

using fluorescence-activated cell sorting (FACS) for accurate screening

Methodology Applied

Scientific EffectFluorescence: Fluorescence

Data Source

PatentEP2064337B1A FACS-and reporter protein-based system for high throughput development of therapeutic proteins

Publication Date: 2012.07.18 GENZYME CORP

Figure 1
Figure 2A
Figure 2B

AI summary

Methods are disclosed to identify, select and produce a clonal population of recombinant eukaryotic host cells thai stably and highly express a polypeptide of interest. Also disclosed herein are products produced by the disclosed methods and assemblies of components useful to conduct the methods.